MorphoSys AG: Correction of a release from 03/06/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
October 11, 2019 at 11:05 am EDT
Share
DGAP Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Correction of a release from 03/06/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
11.10.2019 / 17:02
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
MorphoSys AG
Street:
Semmelweisstr. 7
Postal code:
82152
City:
Planegg Germany
Legal Entity Identifier (LEI):
529900493806K77LRE72
2. Reason for notification
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
X
Other reason: Acquistion and Merger with Oppenheimer Funds Inc. : please see Section 10
3. Details of person subject to the notification obligation
Legal entity: Invesco Ltd. City of registered office, country: Hamilton, Bermuda
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
AIM INTERNATIONAL MUTUAL FUNDS (INVESCO INTERNATIONAL MUTUAL FUNDS)
5. Date on which threshold was crossed or reached:
24 May 2019
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
7.58 %
0.00 %
7.58 %
31839572
Previous notification
3.03 %
0.00 %
3.03 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE0006632003
0
2414177
0.00 %
7.58 %
Total
2414177
7.58 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
Invesco Ltd.
%
%
%
Invesco Holding Company Limited
%
%
%
Invesco Holding Company(US), Inc.
%
%
%
Oppenheimer Acquisition Corporation
%
%
%
Oppenheimerfunds, Inc.
%
%
%
OFI Global Asset Management, Inc.
%
%
%
Invesco Group Services, Inc.
%
%
%
Invesco Advisers, Inc.
7.52 %
%
7.52 %
-
%
%
%
Invesco Ltd.
%
%
%
Invesco Holding Company Limited
%
%
%
Invesco Holding Company(US), Inc.
%
%
%
Oppenheimer Acquisition Corporation
%
%
%
Oppenheimerfunds, Inc.
%
%
%
OFI Global Asset Management, Inc.
%
%
%
Invesco Group Services, Inc.
%
%
%
Invesco Capital Management LLC
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
Acquisition and Merger with Oppenheimer Funds Inc. Please see following link for further information: we will add link here post acquisition; https://ir.invesco.com/investor-relations/press-releases/default.aspx?_ga=2.
153008441.1018859822.1558359393-832691936.1556037780
Date
09 Oct 2019
11.10.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
MorphoSys AG: Correction of a release from 03/06/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
MORPHOSYS AG 
